Episode

Interview #71 Nadia Harhen, General Manager of AI Simulation at SandboxAQ

Podcast
The Artificial Intelligence Podcast
Published
Jul 17, 2025
Duration seconds
1721
Processing state
not_requested
Canonical source
https://podcasters.spotify.com/pod/show/tonyphoang/episodes/Interview-71-Nadia-Harhen--General-Manager-of-AI-Simulation-at-SandboxAQ-e35m3d9
Audio
https://traffic.megaphone.fm/APO1223938171.mp3
JSON
/v1/public/podcasts/the-artificial-intelligence-podcast-3635848/episodes/interview-71-nadia-harhen-general-manager-of-ai-simulation-at-sandboxaq
Markdown
/podcast/the-artificial-intelligence-podcast-3635848/interview-71-nadia-harhen-general-manager-of-ai-simulation-at-sandboxaq.md

Actions

  • POST https://stenobird.com/v1/public/podcasts/the-artificial-intelligence-podcast-3635848/episodes/interview-71-nadia-harhen-general-manager-of-ai-simulation-at-sandboxaq/transcription-requests
    Idempotently request low-priority transcript generation for this episode.
  • GET https://stenobird.com/podcast/the-artificial-intelligence-podcast-3635848/interview-71-nadia-harhen-general-manager-of-ai-simulation-at-sandboxaq.md
    Read the agent-friendly Markdown representation of this episode resource.

Summary

Join Nadia Harhen, General Manager of AI Simulation at SandboxAQ, and Jordan Crivelli-Decker from the Biosim team as they discuss how Large Quantitative Models (LQMs) are revolutionizing drug discovery and materials science by generating synthetic data through physics-based computational chemistry rather than just predicting outcomes like traditional language models. They explain how this approach accelerates drug development timelines, reduces animal testing needs, and enables breakthrough solutions for complex molecular problems that conventional software cannot handle, including work with Nobel laureate Dr. Stanley Prusiner that moved from research to clinical trials in just 18 months. The conversation explores how combining quantum mechanics principles with machine learning creates novel molecular IP across industries from pharmaceuticals to defense applications, bridging the gap between AI capabilities and practical scientific breakthroughs.